Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
To investigate safety and antitumor activity of SGN-30 in patients with Hodgkin's Disease and
anaplastic large cell lymphoma (ALCL).
As of March 22, 2005, interim analysis of the Hodgkin's Disease (HD) arm has been completed
per the statistical plan in the protocol. SG030-0003 is now closed to further recruitment of
HD patients.